Literature DB >> 8527119

Inactivation of DNA by beta-propiolactone.

P Perrin1, S Morgeaux.   

Abstract

beta-propiolactone (BPL) is an alkylating agent which reacts with many nucleophilic reagents including nucleic acids and proteins. BPL modifies the structure of nucleic acids after reaction mainly with purine residues (notably guanine). It induces nicks in DNA, cross-linking between DNA and proteins as well as between the DNA strands in the double helix. Consequently, BPL is widely used for the inactivation of viruses (DNA and RNA viruses). Moreover, it alters the capability of residual/contaminating cell DNA to be used as template by various polymerases. Thus, BPL reduces the risks associated with residual/contaminating cell DNA in biologicals.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527119     DOI: 10.1006/biol.1995.0034

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  20 in total

1.  Molecular identification of the vaccine strain from the inactivated oil emulsion H9N2 low pathogenic avian influenza vaccine.

Authors:  Jun Gu Choi; Youn Jeong Lee; Ji Yeon Kim; Yeon Hee Kim; Mi Ra Paek; Dong Kun Yang; Seong Wan Son; Jae Hong Kim
Journal:  J Vet Sci       Date:  2010-06       Impact factor: 1.672

2.  Autotransporter-based antigen display in bacterial ghosts.

Authors:  Anna Hjelm; Bill Söderström; David Vikström; Wouter S P Jong; Joen Luirink; Jan-Willem de Gier
Journal:  Appl Environ Microbiol       Date:  2014-11-14       Impact factor: 4.792

3.  Porcine peripheral blood dendritic cells and natural interferon-producing cells.

Authors:  Artur Summerfield; Laurence Guzylack-Piriou; Alexander Schaub; Carlos P Carrasco; Valerie Tâche; Bernard Charley; Kenneth C McCullough
Journal:  Immunology       Date:  2003-12       Impact factor: 7.397

4.  A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.

Authors:  Rohan Keshwara; Katie R Hagen; Tiago Abreu-Mota; Amy B Papaneri; David Liu; Christoph Wirblich; Reed F Johnson; Matthias J Schnell
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

Review 5.  The Bacterial Ghost platform system: production and applications.

Authors:  Timo Langemann; Verena Juliana Koller; Abbas Muhammad; Pavol Kudela; Ulrike Beate Mayr; Werner Lubitz
Journal:  Bioeng Bugs       Date:  2010 Sep-Oct

6.  Reactions of beta-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses.

Authors:  Joost P Uittenbogaard; Bert Zomer; Peter Hoogerhout; Bernard Metz
Journal:  J Biol Chem       Date:  2011-08-25       Impact factor: 5.157

7.  Protection against Shiga-Toxigenic Escherichia coli by Non-Genetically Modified Organism Receptor Mimic Bacterial Ghosts.

Authors:  Adrienne W Paton; Austen Y Chen; Hui Wang; Lauren J McAllister; Florian Höggerl; Ulrike Beate Mayr; Lucy K Shewell; Michael P Jennings; Renato Morona; Werner Lubitz; James C Paton
Journal:  Infect Immun       Date:  2015-06-22       Impact factor: 3.441

8.  Production of a Sindbis/Eastern Equine Encephalitis chimeric virus inactivated cell culture antigen.

Authors:  C H Goodman; B J Russell; J O Velez; J J Laven; D A Bagarozzi; J L Moon; K Bedi; B W Johnson
Journal:  J Virol Methods       Date:  2015-07-20       Impact factor: 2.014

9.  Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling.

Authors:  Marcel Jonges; Wai Ming Liu; Erhard van der Vries; Ronald Jacobi; Inge Pronk; Claire Boog; Marion Koopmans; Adam Meijer; Ernst Soethout
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

10.  Quantitation of influenza virus using field flow fractionation and multi-angle light scattering for quantifying influenza A particles.

Authors:  Tatiana Bousse; David A Shore; Cynthia S Goldsmith; M Jaber Hossain; Yunho Jang; Charles T Davis; Ruben O Donis; James Stevens
Journal:  J Virol Methods       Date:  2013-07-31       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.